Silexion Therapeutics Corp (SLXN)

09:21 AM

Silexion Therapeutics Submits Phase 2/3 Trial Application - TipRanks

09:21 AM

08:53 AM

Silexion submits Phase 2/3 trial application to Israel for SIL204 - TipRanks

08:53 AM

08:53 AM

Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 - TradingView — Track All Markets

08:53 AM

08:51 AM

Silexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic Cancer - Quiver Quantitative

08:51 AM

08:40 AM

Silexion Therapeutics Announces Submission of Phase 2/3 - GlobeNewswire

08:40 AM

05:17 AM

Silexion Therapeutics (NASDAQ:SLXN) Now Covered by Litchfield Hills Research - Defense World

05:17 AM

Dec 15, 2025

Silexion Therapeutics initiated with a Buy at Litchfield Hills - TipRanks

Dec 15, 2025

Dec 13, 2025

Bearish Setup: Is Silexion Therapeutics Corp Equity Warrant stock recession proof2025 Momentum Check & AI Forecasted Entry/Exit Points - moha.gov.vn

Dec 13, 2025

Dec 06, 2025

Silexion Shares Decline After Update on German Regulatory Review - MSN

Dec 06, 2025

Dec 05, 2025

Silexion Therapeutics (SLXNW) Stock Analysis Report | Financials & Insights - Benzinga

Dec 05, 2025

Dec 05, 2025

How buybacks impact Silexion Therapeutics Corp stock valueProfit Target & Intraday High Probability Setup Alerts - Newser

Dec 05, 2025

Dec 03, 2025

Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment - TipRanks

Dec 03, 2025

Dec 02, 2025

Silexion Therapeutics drops 18%, prices $5M share offering - MSN

Dec 02, 2025

Dec 02, 2025

Silexion receives positive feedback from German Health Authority for SIL204 - TipRanks

Dec 02, 2025

Dec 02, 2025

Silexion Therapeutics (SLXN) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 02, 2025

Silexion stock falls after receiving German regulatory feedback By Investing.com - Investing.com Canada

Dec 02, 2025

Dec 02, 2025

Silexion stock falls after receiving German regulatory feedback - Investing.com

Dec 02, 2025

Dec 02, 2025

Silexion Therapeutics receives positive feedback from German health authority on design of phase 2/3 clinical trial - marketscreener.com

Dec 02, 2025

Dec 02, 2025

Silexion Therapeutics Gains Positive Feedback for SIL204 Trial - TipRanks

Dec 02, 2025

Dec 02, 2025

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - GlobeNewswire

Dec 02, 2025

Dec 02, 2025

How Silexion Therapeutics Corp Equity Warrant stock reacts to Fed rate cuts2025 Buyback Activity & Weekly Stock Breakout Alerts - Newser

Dec 02, 2025

Nov 28, 2025

Aug Mood: Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Catalysts & Consistent Profit Trade Alerts - moha.gov.vn

Nov 28, 2025

Nov 28, 2025

SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan

Nov 28, 2025

Nov 27, 2025

Its Stock Has Paid Off Big Time For Silexion Therapeutics Corp - setenews.com

Nov 27, 2025

Nov 26, 2025

Silexion Therapeutics completes toxicology studies for SIL204 - MSN

Nov 26, 2025

Nov 26, 2025

Silexion stock jumps after toxicology studies show no systemic toxicity - MSN

Nov 26, 2025

Nov 26, 2025

Silexion Completes Toxicology Studies For SIL204; Phase 2/3 Pancreatic Cancer Trial To Begin In Q2 - Nasdaq

Nov 26, 2025

Nov 26, 2025

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - marketscreener.com

Nov 26, 2025

Nov 25, 2025

Silexion stock jumps after toxicology studies show no systemic toxicity By Investing.com - Investing.com Canada

Nov 25, 2025

Nov 25, 2025

Silexion to begin phase 2/3 pancreatic cancer clinical trial in Q2 2026 - marketscreener.com

Nov 25, 2025

Nov 25, 2025

Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026 - TradingView

Nov 25, 2025

Nov 25, 2025

Silexion Completes Toxicology Studies for SIL204 Therapy - TipRanks

Nov 25, 2025

Nov 25, 2025

Silexion Therapeutics Completes Toxicology Studies for SIL204 - TradingView

Nov 25, 2025

Nov 25, 2025

SLXN advances SIL204 toward Phase 2/3 pancreatic cancer study - Stock Titan

Nov 25, 2025

Nov 25, 2025

Silexion Therapeutics Reports Successful Toxicology Study Results for SIL204, Paving the Way for Upcoming Phase 2/3 Clinical Trial in Pancreatic Cancer - Quiver Quantitative

Nov 25, 2025

Nov 25, 2025

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer - Sahm

Nov 25, 2025

Nov 21, 2025

Can Silexion Therapeutics Corp hit a new high this monthJuly 2025 Closing Moves & Free High Return Stock Watch Alerts - newser.com

Nov 21, 2025

Nov 20, 2025

Silexion Therapeutics Corp (SLXN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 20, 2025

Nov 20, 2025

Why Silexion Therapeutics Corp stock is rated strong buyQuarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com

Nov 20, 2025

Nov 19, 2025

Will Silexion Therapeutics Corp Equity Warrant price bounce be sustainableJuly 2025 Intraday Action & Safe Entry Point Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Real time alert setup for Silexion Therapeutics Corp Equity Warrant performance - newser.com

Nov 19, 2025

Nov 19, 2025

Will Silexion Therapeutics Corp outperform the marketTrade Signal Summary & Consistent Return Strategy Ideas - newser.com

Nov 19, 2025

Nov 19, 2025

How Silexion Therapeutics Corp Equity Warrant stock performs in high volatility marketsDollar Strength & Safe Swing Trade Setup Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Applying sector rotation models to Silexion Therapeutics Corp Equity WarrantProfit Target & Risk Controlled Stock Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Relative strength of Silexion Therapeutics Corp in sector analysisEntry Point & Verified Momentum Watchlists - newser.com

Nov 19, 2025